HIV-1 Entry and Fusion Inhibitors Market is Anticipated to Exhibit a CAGR of 5.5% from 2023 to 2031
Newark, New Castle, USA, May 19, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports calculated the global market size for H*IV-1 entry and fusion inhibitors* in 2022 and is expected to expand at a steady revenue *CAGR of 5.5% by 2031*.
Analysis of the global market for HIV-1 entry and fusion inhibitors indicates that market revenue share is likely to increase significantly during the forecast period. HIV targets the cells of the immune system in the body. The virus has to enter these cells to reproduce. These cells release copy after copy, which spreads to other cells.
*Key Takeaways: *
· The increasing prevalence of HIV-1 infection is driving the market revenue share.
· The growing demand for effective HIV treatment options drives market demand.
· The development of new and innovative entry and fusion inhibitors by pharmaceutical companies is increasing the market revenue growth rapidly.
*Request a Free Sample PDF: https://www.growthplusreports.com/inquiry/request-sample/hiv1-entry-and-fusion-inhibitors-market/8989*
* HIV-1 Entry and Fusion Inhibitors Market Scope*
*Report Attribute* *Details*
CAGR 5.5%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Type, Route of Administration, End User, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
*Recent Development in the HIV-1 Entry and Fusion Inhibitors Market: *
· In July 2021, Positive results from the phase 3 TALENT clinical study were released by Frontier Biotechnologies. Albuvirtide, a brand-new long-acting HIV-1 fusion inhibitor, is the subject of the world's first phase 3 clinical trial in an Asian population.
*Competitive Landscape*
The top companies operating in the global market for HIV-1 entry and fusion inhibitors include:
· Theratechnologies Inc.
· GSK Plc.
· Genentech
· Pfizer Inc.
· Frontier Biotechnologies* *
*Market Drivers and Restraints: *
The global HIV-1 entry and fusion inhibitors market revenue is driven by the rising disease prevalence, awareness for early diagnosis and treatment, increasing R&D for high-class treatments, and rising demand for precise therapeutics.
However, due to unawareness among the population and high costs, the HIV-1 entry and fusion inhibitors market revenue growth is likely to be restrained.
*Market Segmentation: *
· Based on* *type, the global HIV-1 Entry and fusion inhibitors market is segmented into* *Fusion Inhibitor (Enfuvirtide)*, *CCR5 Antagonist (Selzentry), Post-attachment Inhibitor (Trogarzo)*, *and Attachment Inhibitor (Rukobia).
· Based on the route of administration, HIV-1 Entry and fusion inhibitors market is segmented into oral and injectable.
*Request for Customization – https://www.growthplusreports.com/inquiry/customization/hiv-1-entry-and-fusion-inhibitors-market/8989*
*Segmentation By Type*
Based on the types, the enfuvirtide segment dominates the global HIV-1 entry and fusion inhibitors market with the largest revenue share as it is the first fusion inhibitor approved by the US FDA. Its long-term use has been limited by injection site reactions, the rapid development of resistant viruses, and high production costs. A rise in the prevalence of AIDS or infections by the human immunodeficiency virus (HIV) contributes to market revenue growth.
Regional Growth Dynamics
Based on the region, North America, with a sizable revenue share, dominates the global HIV-1 entry and fusion inhibitors market. One of the strongest areas, North America, considerably impacts the worldwide market for HIV entry and Fusion inhibitors. The construction of a technologically advanced healthcare system, patients' increasing awareness of disease-reversing medications, and supportive reimbursement policies are all factors in the region's market revenue growth. Additionally, increasing government spending on HIV prevention and treatment programs should benefit the market during the forecast period.
*Report Coverage *
Growth Plus Reports studied the world market for HIV-1 entry and fusion inhibitors extensively. We analyzed the market at the basic market traits, important investment zones, regional growth analytics, ten years of revenue projections, rival market participants, and mergers and acquisitions.
*Table of Content*
1. *INTRODUCTION*
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years – 2021
2. Base Year – 2022
3. Forecast Years – 2023 to 2031
3. Currency Used in the Report
2. *RESEARCH METHODOLOGY *
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. *PREMIUM INSIGHTS*
1. Current Market Trends (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2022)
3. Regulatory Landscape
4. *MARKET DYNAMICS*
1. Drivers
2. Restraints/Challenges
3. Opportunities
5. *GLOBAL HIV-1 ENTRY AND FUSION INHIBITORS MARKET - ANALYSIS & FORECAST, BY TYPE*
1. Fusion Inhibitor (Enfuvirtide)
2. CCR5 Antagonist (Selzentry)
3. Post-attachment Inhibitor (Trogarzo)
4. Attachment Inhibitor (Rukobia)
6. *GLOBAL HIV-1 ENTRY AND FUSION INHIBITORS MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION*
1. Oral
2. Injectable
*HIV-1 ENTRY AND FUSION INHIBITORS MARKET TOC*
*Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8989*
*VALUE PROPOSITIONS RELATED TO THE REPORT*:
· Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
· Comprehensive quantitative and qualitative insights at segment and sub-segment level
· Covid 19 impact trends and perspective
· Granular insights at global/regional/country level
· Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
· Blanket coverage on competitive landscape
· Winning imperatives
· Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.
*CUSTOMIZATION OPTIONS*:
· Distributor Landscape Assessment
· Pricing Intelligence
· Customer Base Assessment
· Investment & Initiatives Analysis
· 'Business Profile' of Key Players
*Schedule a call with our analyst: **https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction*
*Visit our report store at - **https://www.growthplusreports.com/report-store*
*Browse more latest healthcare reports:*
*Life Support Systems Market by Device Type (Ventilators, Extracorporeal Oxygenator), End User (Trauma Centers, Hospitals) – Global Outlook & Forecast 2023-2031*
*Protein Labeling Market by Product (Reagents, Kits), Labeling Method (In-Vivo Labeling, In-Vitro Labeling), Application (Protein Microarray, Mass Spectrometry), End User (Hospitals, Biopharmaceutical Companies) – Global Outlook & Forecast 2023-2031*
*Automated Visual Field Analyzer Market by Type (Static, Kinetic), Application (Glaucoma, Age-related Macular Degeneration, Scotoma, Others), End User (Hospitals, Eye Clinics) – Global Outlook & Forecast 2023-2031*
*Bone Metabolism Test Market by Test Types (Bone Marker Test, Immunoassay), Application (Hyperparathyroidism, Hypoparathyroidism) – Global Outlook & Forecast 2023-2031*
*Transient Elastography Device Market by Technology (Vibration Controlled Transient Elastography and Controlled Attenuation Parameter), Modality (Standalone and Portable), End User (Hospitals, Diagnostics Centers) – Global Outlook & Forecast 2023-2031*
*About Us:*
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
CONTACT: Manan Sethi
Director, Market Insights
Email: sales@growthplusreports.com
256 Chapman Road
STE 105-4, Newark,
New Castle - 19702, USA
Phone no: +1 888 550 5009
Web: https://www.growthplusreports.com/